Dentistry is moving through a quiet but profound technological shift. For much of modern clinical practice, biomaterials have been judged primarily by their strength, seal, handling, durability, and biocompatibility. Those criteria still matter. But the next generation of dental biomaterials is being designed to do far more than fill, seal, bond, or replace.
The emerging frontier is therapeutic biomaterials: materials that sense the oral environment, deliver drugs locally, modulate inflammation, guide stem cell behavior, and support tissue regeneration.
A recent review, The Future of Biomaterials in Dentistry: Innovations in Drug Delivery and Regenerative Medicine, captures this transition clearly. The central theme is that dental materials are evolving from passive structural substitutes into biologically active platforms for precision oral healthcare.
This has enormous implications for endodontics, periodontics, implant dentistry, oral oncology, pediatric dentistry, and regenerative dental medicine.
Smart drug delivery in the oral environment
The oral cavity is one of the most challenging sites for drug delivery. Saliva, biofilms, enzymatic activity, mastication, pH changes, inflammation, and anatomical complexity all interfere with sustained therapeutic concentration.
Traditional rinses, gels, and systemic antibiotics often struggle with this problem. They may be cleared too quickly, distributed too broadly, or require repeated dosing. Smart local drug delivery systems attempt to solve that problem by placing the therapeutic agent where it is needed, for as long as it is needed, and at a concentration that may reduce unnecessary systemic exposure.
This is where nanoparticles, hydrogels, microspheres, mucoadhesive films, nanofibers, and scaffold-based systems become clinically important.
Instead of delivering a drug into the whole body and hoping enough reaches the periodontal pocket, peri-implant sulcus, root canal system, extraction socket, mucosal lesion, or osseous defect, the therapeutic platform can be engineered for local retention and controlled release.
That concept alone represents a major shift in dental therapeutics.
Stimuli-responsive biomaterials: treatment that reacts to disease
One of the most exciting areas is stimuli-responsive drug delivery. These systems can be designed to respond to local biological cues such as acidic pH, oxidative stress, inflammatory enzymes, or matrix metalloproteinases.
In practical terms, this means a material may release an antimicrobial, anti-inflammatory agent, growth factor, or regenerative signal in response to the very conditions that define disease activity.
An inflamed periodontal pocket, an infected root canal environment, or a biofilm-rich peri-implant defect is not chemically neutral. It carries signals. Future dental biomaterials may increasingly be designed to read those signals and respond.
This is the conceptual bridge between material science and biologically informed dentistry.
Endodontics and the return of local therapeutics
Endodontics is especially well suited for this conversation. The root canal system is anatomically complex, biologically dynamic, and often difficult to disinfect completely. Persistent biofilms, dentinal tubule penetration, apical anatomy, immature roots, and regenerative endodontic procedures all create a need for more refined therapeutic delivery.
The review highlights multiple local drug delivery strategies relevant to endodontics, including PLGA-based microspheres, chitosan nanoparticles, antibiotic-loaded hydrogels, nanofibrous scaffolds, photodynamic therapy platforms, and drug-eluting constructs.
For regenerative endodontics, the ideal material is not simply antimicrobial. It must balance disinfection with stem cell compatibility, scaffold architecture, bioactive signaling, and the possibility of continued root development or pulp-like tissue repair.
That balance is difficult. Overly aggressive disinfection can impair the very cells needed for regeneration. Insufficient disinfection can compromise the outcome. Controlled local delivery may offer a more biologically intelligent middle ground.
This is where future endodontic therapeutics may become less about “placing a medicament” and more about engineering a temporary biologic microenvironment.
Hydrogels, scaffolds, and biologic signaling
Hydrogels are particularly attractive because they can conform to irregular defects, carry drugs or nanoparticles, support cell migration, and degrade over time. Injectable hydrogels may be useful in periodontal defects, oral mucosal lesions, extraction sockets, regenerative endodontic spaces, and craniomaxillofacial reconstruction.
Scaffolds are also moving beyond their traditional role as passive frameworks. Newer scaffold systems can combine structural support with drug delivery, antimicrobial release, growth factor presentation, and immunomodulatory activity.
This is crucial because regeneration is not merely the presence of cells. It requires a coordinated sequence of vascularization, inflammation control, extracellular matrix formation, mineralization, and tissue integration.
The most important future dental biomaterials may be those that guide this sequence rather than simply occupy space.
Additive manufacturing and patient-specific regeneration
Additive manufacturing, including 3D printing and bioprinting, adds another dimension. Patient-specific scaffolds can be designed from imaging data and fabricated with controlled porosity, mechanical architecture, degradation behavior, and spatially organized bioactive cues.
In dentistry, this has particular relevance for alveolar ridge defects, periodontal regeneration, implant site development, post-traumatic reconstruction, and potentially dentin-pulp complex engineering.
The long-term vision is compelling: a scaffold designed not only to fit the defect, but to deliver antibiotics, growth factors, vascular cues, or gene-based signals in a controlled pattern over time.
That is personalized regenerative dentistry in its most literal sense.
Oral oncology and dual-function materials
The review also discusses dual-function platforms for oral cancer therapy and tissue repair. This is an important area because surgical management of oral cancer may leave significant hard and soft tissue defects.
Future biomaterials may help combine localized anti-cancer therapy with regenerative support. For example, drug-loaded nanofibers, injectable peptide hydrogels, mucoadhesive patches, and nanoparticle-based photodynamic therapy could potentially provide localized tumor control while supporting healing of the surrounding oral tissues.
This remains an emerging and complex area, but it illustrates a larger point: the same platform may eventually be designed to deliver therapy, reduce systemic toxicity, and support reconstruction.
The translational caution: safety, regulation, and evidence
The excitement around nanotechnology and regenerative biomaterials must be balanced with caution.
Nano-enabled dental materials raise important questions about toxicity, biodistribution, immune response, protein corona formation, long-term accumulation, occupational exposure, degradation products, and regulatory classification.
A material that performs beautifully in vitro may behave differently in saliva, biofilm, inflamed tissue, bone, mucosa, or a mechanically loaded oral environment. Dentistry needs not only innovation, but also standardized testing models that better reflect clinical reality.
The most successful future technologies will not simply be the most biologically sophisticated. They will be the ones that demonstrate predictable safety, manufacturability, durability, regulatory clarity, and clinical benefit.
Why this matters now
For clinicians, the future of dental biomaterials will likely arrive gradually rather than all at once. We are already familiar with some early forms of local drug delivery, bioactive materials, bioceramics, guided tissue regeneration, antimicrobial surfaces, and scaffold-based repair.
What is changing is the degree of integration.
The next generation will not separate material selection from therapeutic strategy. The material itself may become part of the therapy.
In endodontics, that could mean antimicrobial scaffolds that preserve stem cell viability. In periodontics, it could mean injectable hydrogels that release anti-inflammatory and osteogenic signals. In implant dentistry, it could mean surface-functionalized implants that reduce early infection risk and enhance osseointegration. In oral medicine, it could mean mucoadhesive films that deliver drugs locally to mucosal lesions with minimal systemic exposure.
The future of dental therapeutics is not simply more powerful drugs. It is smarter delivery.
Radar Insight
The most important message is not that dentistry is becoming more “high-tech.” It is that biomaterials are becoming biologically accountable.
A future dental material will increasingly be judged not only by how it handles, seals, bonds, fills, or supports, but by how intelligently it interacts with tissue biology.
Attribution
This RootRadar Espresso article is an original commentary inspired by: Farjaminejad R, Farjaminejad S, Garcia-Godoy F, Hassani M, Rahimikia K. The Future of Biomaterials in Dentistry: Innovations in Drug Delivery and Regenerative Medicine. Journal of Applied Dentistry and Oral Sciences. 2026.
